A Study of SHR-A1811 in Subjects With Ovarian Cancer

This study is testing SHR-A1811 — an antibody-drug conjugate that delivers chemotherapy directly to cancer cells — in people with ovarian cancer. The drug targets HER2, a protein present on some ovarian cancer cells, and is designed to kill them while minimizing damage to healthy tissue. **You may be eligible if...** - You have ovarian cancer with at least one measurable tumor on a scan - You are in good overall health (ECOG performance status 0 or 1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have active brain metastases causing symptoms that have not been treated - You have serious, uncontrolled heart disease - You have an active autoimmune disease or a history of one - You currently have active hepatitis B or hepatitis C - You have a severe active infection Talk to your doctor to see if this trial is right for you.